Accéder au contenu
Merck

Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits?

Annals of the New York Academy of Sciences (2013-07-17)
Silvie Timmers, Matthijs K C Hesselink, Patrick Schrauwen
RÉSUMÉ

The number of people suffering from metabolic disorders is dramatically increasing worldwide. The need for new therapeutic strategies to combat this growing epidemic of metabolic diseases is therefore also increasing. In 2003, resveratrol was discovered to be a small molecule activator of sirtuin 1 (SIRT1), an important molecular target regulating cellular energy metabolism and mitochondrial homeostasis. Rodent studies have clearly demonstrated the potential of resveratrol to improve various metabolic health parameters. To date, however, only limited clinical data are available that have systematically examined the health benefits of resveratrol in metabolically challenged humans. This short review will give an overview of the currently available clinical studies examining the effects of resveratrol on obesity and type 2 diabetes from a human perspective.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Resvératrol, ≥99% (HPLC)
Supelco
Resvératrol, analytical standard
Resvératrol, European Pharmacopoeia (EP) Reference Standard
Supelco
Resvératrol, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland